If you have been reading about LC-MS/MS and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-09-05. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine in major jurisdictions | Sold as a research chemical; legal status varies |
| Anti-doping status | Prohibited by the World Anti-Doping Agency | Listed under non-approved substances or related category |
| Typical analytical method | LC-MS/MS | Used for detection and confirmation in biological samples |
| Storage temperature | −20 °C or lower for solid | Desiccated and protected from light |
| Common solution solvents | DMSO; ethanol | Aqueous solubility is limited |
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
== Expression == In insects, CSPs are found throughout the whole insect development process from eggs and larvae to nymphal and adult stages [4, 16-19]. In locusts, they are mainly expressed in the antennae, tarsi and legs, and found to be associated with phase change [3-4, 20-22]. CSPs are not the apanage of insects. They are also expressed in many various organisms such as crustacean, shrimp and many other arthropod species [23]. However, they are not specific to the arthropod kingdom. They are also expressed at the level of the bacterial superkingdom, demonstrating their existence not only in eukaryotes, but also in prokaryote organisms [23-24]. Prokaryote CSPs are twins or identical twins to insect CSPs [24]. They have been reported from bacterial species such as coccobacillus Acinetobacter baumannii, Macrococcus/Staphylococcus caseolyticus, the filamentous actinomycete Kitasatospora griseola, an Actinobacteria genus in the family Streptomycetaceae, and Escherichia coli (E. coli) which are known as common bacteria from the digestive tract, main prokaryotic secondary metabolites, opportunistic multi-drug resistant pathogens, high positive cytochrome c oxidase reactions, and symbionts of multiple insect species [24]. Their existence has been mentioned in plants, but this still needs to be demonstrated experimentally [25-26]. CSPs can be extracted from wasp venom [27]. In moths, nearly all CSPs are expressed in the female pheromone gland [9-14].
radical Also free radical. Any atom, molecule, or ion that has at least one unpaired valence electron. With few exceptions, such unpaired electrons make radicals highly chemically reactive, and therefore organic radicals are usually short-lived.
The United States was one of the "Four Policemen" who met to plan the post-war world, alongside the United Kingdom, the Soviet Union, and China. The U.S. emerged relatively unscathed from the war, with even greater economic power and international political influence.
Sources: en.wikipedia.org
Rivastigmine, sold under the brand name Exelon among others, is an acetylcholinesterase inhibitor used for the treatment of dementia associated with Alzheimer's disease and with Parkinson's disease. Rivastigmine can be administered orally or via a transdermal patch; the latter form reduces the prevalence of side effects, which typically include nausea and vomiting. Rivastigmine is eliminated through the urine, and appears to have relatively few drug-drug interactions. It was patented in 1985 and came into medical use in 1997.
They are used in many dietary probiotic supplements. Theralac contains the strains Bifidobacterium lactis BI-07 and Bifidobacterium lactis BL-34 (also called BI-04) in its probiotic capsule. Bifidobacterium animalis lactis HN019 (DR10) is a strain from Fonterra licensed to DuPont, which markets it as HOWARU Bifido. It is sold in a variety of commercial probiotics, among them Tropicana Products Essentials Probiotics, Attune Wellness Bars and NOW Foods Clinical GI Probiotic. Fonterra has a yogurt that is sold in New Zealand called Symbio Probalance, where the strain is labelled as DR10.
Given that the version of the theory we are testing is universalistic in its claims – that 'hegemony leads to balance … through all of the centuries we can contemplate' – case selection is unimportant. Any significant counterexample falsifies the universal claim; eight such examples demolish it. Wohlforth et al. state that systemic hegemony is likely under two historically common conditions: First when the rising hegemon develops the ability to incorporate and effectively administer conquered territories. And second, when the boundaries of the international system remain stable, and no new major powers emerge from outside the system. When the leading power can administer conquests effectively so they add to its power and when the system's borders are rigid, the probability of hegemony is high. The argument of universal reproduction of anarchy can be correct in the European context, "whereas a systematic survey of world history reveals that multipolarity has frequently given way to unipolarity or hegemony." Henry Kissinger, historian by profession, noted that "theories of the balance of power often leave the impression that it is the natural form of international relations. In fact, balance-of-power systems have existed only rarely in history." Yet based on these rare occurrences, many realists "elevate a fact of life … into a guiding principle of world order." Earlier, political scientist Martin Wight had drawn a conclusion with unambiguous implication for the modern world:
Sources: en.wikipedia.org
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.
Laboratories typically use LC-MS/MS to detect SR9009 and related compounds in urine or blood. The method is sensitive but depends on sample collection timing. Confirmatory analysis follows quality-control procedures.
Solid material is generally kept cold, dry, and protected from light. Solutions are often stored in sealed containers at low temperature. Stability beyond recommended periods is not well documented.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.